期刊
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
卷 302, 期 11, 页码 1171-1178出版社
AMER MEDICAL ASSOC
DOI: 10.1001/jama.2009.1320
关键词
-
资金
- Orebro University Hospital
- Swedish Society of Medicine
- Swedish Research Council
- Sven Jerring Foundation
- Orebro Society of Medicine
- Karolinska Institutet
- Clas Groschinsky Foundation
- Juhlin Foundation
- Majblomman Foundation
- Uppsala-Orebro Regional Research Council
- Swedish Celiac Society
Context Studies of mortality in celiac disease have not taken small-intestinal pathology into account. Objective To examine mortality in celiac disease according to small-intestinal histopathology. Design, Setting, and Patients Retrospective cohort study. We collected data from duodenal/jejunal biopsies taken between July 1969 and February 2008 on celiac disease (Marsh stage 3: villous atrophy; n=29 096 individuals) and inflammation (Marsh stage 1-2; n=13 306) from all 28 pathology departments in Sweden. A third cohort consisted of individuals with latent celiac disease from 8 university hospitals (n=3719). Latent celiac disease was defined as positive celiac disease serology in individuals with normal mucosa (Marsh stage 0). Through linkage with the Swedish Total Population Register, we estimated the risk of death through August 31, 2008, compared with age-and sex-matched controls from the general population. Main Outcome Measure All-cause mortality. Results There were 3049 deaths among patients with celiac disease, 2967 with inflammation, and 183 with latent celiac disease. We found an increased hazard ratio (HR) for death in celiac disease (HR, 1.39; 95% confidence interval [CI], 1.33-1.45; median follow-up, 8.8 years), inflammation (HR, 1.72; 95% CI, 1.64-1.79; median follow-up, 7.2 years), and latent celiac disease (HR, 1.35; 95% CI, 1.14-1.58; median follow-up, 6.7 years). The absolute mortality rate was 10.4 (95% CI, 10.0-10.8) per 1000 person-years in celiac disease, 25.9 (95% CI, 25.0-26.8) in inflammation, and 6.7 (95% CI, 5.7-7.6) in latent celiac disease. Excess mortality was 2.9 per 1000 person-years in celiac disease, 10.8 in inflammation, and 1.7 in latent celiac disease. This risk increase was also seen in children. Excluding the first year of follow-up, HRs decreased somewhat. Conclusion Risk of death among patients with celiac disease, inflammation, or latent celiac disease is modestly increased. JAMA. 2009; 302(11): 1171-1178
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据